Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-3471
Abstract: Purpose: While the detection of AR-V7 in circulating tumor cells (CTC) is associated with resistance to abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), it only accounts for a minority of this… read more here.
Keywords: abiraterone enzalutamide; cin; circulating tumor; treated abiraterone ... See more keywords
Circulating androgen receptor and serum chromogranin A in castration-resistant prostate cancers (CRPC) patients treated with abiraterone and enzalutamide.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.6_suppl.160
Abstract: 160Background: Circulating aberrations (copy number/point mutation] of androgen receptor (AR) as well as serum chromogranin A (CgA) have been associated to treatment response and clinical outcome in CRPC patients (pts) treated with abiraterone (abi)/enzalutamide(enza). Methods:… read more here.
Keywords: treated abiraterone; androgen receptor; crpc patients; serum chromogranin ... See more keywords
Prognostic factors for patients treated with abiraterone
Sign Up to like & getrecommendations! Published in 2019 at "Future Science OA"
DOI: 10.2144/fsoa-2019-0079
Abstract: Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate… read more here.
Keywords: factors patients; prognostic factors; patients treated; treated abiraterone ... See more keywords
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14092219
Abstract: Simple Summary Prostate cancer is a very common disease in men. Nowadays several life-prolonging therapies are available, also efficient in the metastatic setting. However, it is important to choose the best approach for each patient,… read more here.
Keywords: dna ctdna; ctdna; treated abiraterone; gain ... See more keywords